US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Parabilis Medicines

38.69

-0.6700-1.70%

Volume:88.32K

Turnover:3.45M

Market Cap:4.80B

PE:-1.65

High:40.56

Open:39.42

Low:38.49

Close:39.36

52wk High:41.49

52wk Low:24.51

Shares:124.00M

Float Shares:33.50M

Volume Ratio:0.75

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-23.4458

EPS(LYR):-60.0402

ROE:--

ROA:--

PB:4.58

PE(LYR):-0.64

Loading ...

Overview Company News Filings

Parabilis Medicines Inc : Guggenheim Initiates Coverage with Buy Rating; Target Price $40

THOMSON REUTERS

Major Investor Makes Bold Move in Parabilis Medicines, Inc. Stock

Soleus Capital’s Guy Levy Acquires $10 Million of Parabilis Medicines Common Shares

Parabilis Medicines Files Form 3 Initial Beneficial Ownership Statement for Guy Levy

Parabilis Medicines director Alan Sebulsky reports PBLS common share purchase worth $812,401.11

Parabilis Medicines director Alan Sebulsky reports purchase of 12,500 common shares for $250,000

Parabilis Medicines Closes Initial Public Offering

MT Newswires Live

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

THOMSON REUTERS

Parabilis Medicines off highs, but still up over 50% from IPO price

Movement Alert｜Parabilis Medicines Rises 49.15% in Regular Trading, IPO Debuts with 10x Oversubscription

BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner

BUZZ-Drug developer Parabilis Medicines surges in Nasdaq debut

Stock Track | Parabilis Medicines Soars 66.75% Intraday on Successful IPO Pricing Above Expectations

NASDAQ TRADE HALT IPO SECURITY RELEASED FOR QUOTATION AT 11:12 AM

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 09:30 AM

Parabilis Medicines to Raise $745 Million in IPO, Private Offering

MT Newswires Live

Parabilis Medicines, a Rising Star in Cancer Peptide Therapy, Prices IPO Above Range with 10x Oversubscription, Raising $745 Million

Parabilis Medicines 33.5M share IPO priced at $20.00

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

Parabilis Medicines Boosts IPO to 33.3 Million Shares From 25 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/PBLS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PBLS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBLS\",,,,,undefined,":{"symbol":"PBLS","market":"US","secType":"STK","nameCN":"Parabilis Medicines","latestPrice":38.69,"timestamp":1787584997656,"preClose":39.36,"halted":0,"volume":88321,"delay":0,"changeRate":-0.01702235772357728,"floatShares":33500000,"shares":124000000,"eps":-23.44581,"marketStatus":"Trading","change":-0.67,"latestTime":"08-24 11:23:21 EDT","open":39.42,"high":40.56,"low":38.485,"amount":3447145.313256,"amplitude":0.052718,"askPrice":38.77,"askSize":300,"bidPrice":38.61,"bidSize":337,"shortable":3,"etf":0,"ttmEps":-23.44581,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1781064000000,"exchange":"NASDAQ","adjPreClose":39.36,"preHourTrading":{"tag":"盘前","latestPrice":39.25,"preClose":39.36,"latestTime":"09:21 EDT","volume":47,"amount":1840.66006,"timestamp":1787577681390,"change":-0.11,"changeRate":-0.002795,"amplitude":0.008892},"postHourTrading":{"tag":"盘后","latestPrice":39.36,"preClose":39.36,"latestTime":"19:30 EDT","volume":1113,"amount":43800.34,"timestamp":1787355007379,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.751578,"impliedVol":0.5669,"impliedVolPercentile":0.2222},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBLS\",,,,,undefined,":{"symbol":"PBLS","floatShares":33500000,"roa":"--","roe":"--","lyrEps":-60.040199,"volumeRatio":0.751578,"shares":124000000,"dividePrice":0,"high":40.56,"amplitude":0.052718,"preClose":39.36,"low":38.485,"week52Low":24.51,"pbRate":"4.58","psRate":"32415.95","week52High":41.4899,"institutionHeld":0,"latestPrice":38.69,"committee":0.058085,"eps":-23.44581,"divideRate":0,"volume":88321,"delay":0,"ttmEps":-23.44581,"open":39.42,"prevYearClose":20,"prevWeekClose":39.36,"prevMonthClose":33.98,"prevQuarterClose":27.37,"fiveDayClose":37.22,"twentyDayClose":31.82,"sixtyDayClose":20},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBLS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"PBLS","fiscalQuarterEnding":"2026/06","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-2.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBLS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBLS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1786766400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PBLS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PBLS","date":"2026-08-21","current":-1.678765,"percent":0.183673,"low":-31.159897,"twenty":-28.53843,"median":-25.283578,"eighty":-22.890572,"high":-15.535256,"avg":-25.511867,"sd":3.035266,"marketCap":4889445639},"quantilePoints":[{"date":"2026-06-12","current":-23.423744,"twenty":-24.021896,"median":-23.423744,"eighty":-18.690651,"marketCap":3580998591},{"date":"2026-06-18","current":-21.681158,"twenty":-23.280127,"median":-22.147598,"eighty":-21.001488,"marketCap":3314593719},{"date":"2026-06-26","current":-21.956025,"twenty":-22.933884,"median":-22.426629,"eighty":-21.561216,"marketCap":3356615076},{"date":"2026-07-02","current":-23.122126,"twenty":-23.423744,"median":-22.77646,"eighty":-21.681158,"marketCap":3534887500},{"date":"2026-07-10","current":-25.287743,"twenty":-24.420664,"median":-22.938881,"eighty":-21.956025,"marketCap":3865964860},{"date":"2026-07-17","current":-24.204934,"twenty":-24.912925,"median":-23.706058,"eighty":-22.147598,"marketCap":3700426180},{"date":"2026-07-24","current":-27.328421,"twenty":-25.279414,"median":-24.204934,"eighty":-22.705661,"marketCap":4177941603},{"date":"2026-07-31","current":-26.886968,"twenty":-25.665893,"median":-24.321545,"eighty":-22.738979,"marketCap":4110452756},{"date":"2026-08-07","current":-29.635636,"twenty":-26.527142,"median":-24.625564,"eighty":-22.753971,"marketCap":4530666328},{"date":"2026-08-14","current":-29.710599,"twenty":-28.289622,"median":-24.912925,"eighty":-22.788954,"marketCap":4542126698},{"date":"2026-08-21","current":-28.671719,"twenty":-28.53843,"median":-25.283578,"eighty":-22.890572,"marketCap":4889445639}],"updateTime":1787576366550},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBLS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649861053","title":"Parabilis Medicines Inc : Guggenheim Initiates Coverage with Buy Rating; Target Price $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2649861053","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649861053?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:51","pubTimestamp":1783306283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN438001:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647586277","title":"Major Investor Makes Bold Move in Parabilis Medicines, Inc. Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2647586277","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647586277?lang=en_us&edition=fundamental","pubTime":"2026-06-30 10:05","pubTimestamp":1782785118,"startTime":"0","endTime":"0","summary":"New insider activity at Parabilis Medicines, Inc. ( ($PBLS) ) has taken place on June 29, 2026. Significant shareholder Guy Levy has made a major m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-in-parabilis-medicines-inc-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-in-parabilis-medicines-inc-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647370775","title":"Soleus Capital’s Guy Levy Acquires $10 Million of Parabilis Medicines Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2647370775","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647370775?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:41","pubTimestamp":1782744119,"startTime":"0","endTime":"0","summary":"Soleus Capital’s Guy Levy acquires $10 million of Parabilis Medicines common sharesParabilis Medicines Form 4 showed 10% owner Guy Levy increased indirect common stock holdings through affiliated Sole","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL7jZ3x5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Soleus Capital’s Guy Levy Acquires $10 Million of Parabilis Medicines Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647370717","title":"Parabilis Medicines Files Form 3 Initial Beneficial Ownership Statement for Guy Levy","url":"https://stock-news.laohu8.com/highlight/detail?id=2647370717","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647370717?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:39","pubTimestamp":1782743942,"startTime":"0","endTime":"0","summary":"Parabilis Medicines files Form 3 initial beneficial ownership statement for Guy LevyParabilis Medicines Form 3 filed for Guy Levy, flagged as a 10% owner, tied to Soleus Capital-managed entities.Repor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL4dC7Hp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644793725","title":"Parabilis Medicines director Alan Sebulsky reports PBLS common share purchase worth $812,401.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2644793725","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644793725?lang=en_us&edition=fundamental","pubTime":"2026-06-17 06:20","pubTimestamp":1781648403,"startTime":"0","endTime":"0","summary":"Parabilis Medicines director Alan Sebulsky reported purchases of 17,500 common shares at weighted-average prices of USD 25.9978 to USD 27.6696.Holdings reported as indirectly owned through Apothecary Capital LLC rose to 30,000 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parabilis Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL32s7BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Parabilis Medicines director Alan Sebulsky reports PBLS common share purchase worth $812,401.11","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643895467","title":"Parabilis Medicines director Alan Sebulsky reports purchase of 12,500 common shares for $250,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2643895467","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643895467?lang=en_us&edition=fundamental","pubTime":"2026-06-16 05:28","pubTimestamp":1781558909,"startTime":"0","endTime":"0","summary":"Parabilis Medicines director Alan Sebulsky disclosed an indirect purchase of 12,500 common shares at USD 20 each.The stake is held through Apothecary Capital LLC, leaving 12,500 shares beneficially owned indirectly following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parabilis Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL1BK30r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Parabilis Medicines director Alan Sebulsky reports purchase of 12,500 common shares for $250,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642234620","title":"Parabilis Medicines Closes Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642234620","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642234620?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:36","pubTimestamp":1781210188,"startTime":"0","endTime":"0","summary":"Parabilis Medicines (PBLS) said Thursday it has closed its upsized initial public offering of about 38.5 million shares, including the full exercise of an overallotment option, at $20.00 each.The clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0823434740.USD","REGN","BK4585","LU0109394709.USD","LU2237438978.USD","PBLS","LU2362540622.SGD","LU1974910355.USD","LU2362541273.HKD","LU0289739699.SGD","LU0053666078.USD","LU0320765992.SGD","LU2023250504.SGD","LU2089984988.USD","LU0823416689.USD","LU0058720904.USD","LU0882574055.USD","BK4588","LU1917777945.USD","LU0889565916.HKD","LU2106854487.HKD","LU2362541513.USD","IPOS","BK4139","LU0823434583.USD","LU0114720955.EUR","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642823190","title":"Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642823190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642823190?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:05","pubTimestamp":1781208311,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0OB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642001478","title":"Parabilis Medicines off highs, but still up over 50% from IPO price","url":"https://stock-news.laohu8.com/highlight/detail?id=2642001478","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642001478?lang=en_us&edition=fundamental","pubTime":"2026-06-11 02:20","pubTimestamp":1781115610,"startTime":"0","endTime":"0","summary":"The shares in afternoon trading are up $10.67 from the $20.00 offer price to $30.67. Published first on TheFly – the ultimate source for real-time,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/parabilis-medicines-off-highs-but-still-up-over-50-from-ipo-price-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/parabilis-medicines-off-highs-but-still-up-over-50-from-ipo-price-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPOS","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158068339","title":"Movement Alert｜Parabilis Medicines Rises 49.15% in Regular Trading, IPO Debuts with 10x Oversubscription","url":"https://stock-news.laohu8.com/highlight/detail?id=1158068339","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158068339?lang=en_us&edition=fundamental","pubTime":"2026-06-11 02:04","pubTimestamp":1781114651,"startTime":"0","endTime":"0","summary":"On June 10, Parabilis Medicines surged 49.15% in regular trading, trading at $29.90/share with trading volume of approximately $102 million. The stock made its public market debut after pricing its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478617","title":"BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642478617?lang=en_us&edition=fundamental","pubTime":"2026-06-11 01:37","pubTimestamp":1781113032,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarnerWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nL6N42I0OG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOOX","00200","IIPR","QCOM","XOMX","XOMZ","BE","EROC","CASY","CGEM","HOOD","SI","CCTG","CRMT","NWMX","HOOZ","MOH","TNGX","CHWY","ODFL","CVX","ILMN","WTI","NKE","AU","PBLS","APA","NEM","SMCI","GNRC","CPOP","AMZW","CAVA","UPS","MSC","AKR","JCI","CNC","CBRL","JILL","DVN","XOM","KIM","SKIL","UHS","FDX","BWA","STTK","AMZN","AMZD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478315","title":"BUZZ-Drug developer Parabilis Medicines surges in Nasdaq debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478315","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642478315?lang=en_us&edition=fundamental","pubTime":"2026-06-11 01:19","pubTimestamp":1781111991,"startTime":"0","endTime":"0","summary":"BUZZ-Drug developer Parabilis Medicines surges in Nasdaq debut** Shares of Parabilis Medicines PBLS.O jump 43% in Nasdaq debut** The drug developer's stock opened at $33.35 apiece vs $20 IPO price** The Cambridge, Massachusetts-based PBLS sold 33.5 million shares in an upsized offering above its marketed range of $17 and $19 apiece to raise $670 million** Parabilis, whose pipeline is focused on various cancers and tumors, was co-founded in 2015 by longtime Harvard professor Greg Verdine** Separately, PBLS agreed to sell $75 million worth of shares in a concurrent private placement to Regeneron Pharmaceuticals REGN.O ** \"The upsize  a strong signal that investors are increasingly willing to fund ambitious biotechs again, especially when those companies come with external validation and a path into late-stage development\" - IPOX Research Associate Lukas Muehlbauer** \"Innovative biotech IPOs can also catch a premium with M&A remaining highly active as an important exit route for recent li","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nL6N42I14U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","BK4139","LU1917777945.USD","LU1974910355.USD","LU2023250504.SGD","LU0889565916.HKD","LU0289739699.SGD","LU0109394709.USD","LU0114720955.EUR","LU2089984988.USD","LU0823434583.USD","PBLS","LU0058720904.USD","NUVL","LU2362540622.SGD","LU2362541513.USD","BK4539","LU2106854487.HKD","LU0320765992.SGD","REGN","LU2468319806.SGD","LU0823416689.USD","BK4585","LU2362541273.HKD","LU0823434740.USD","BK4588","LU0053666078.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139874515","title":"Stock Track | Parabilis Medicines Soars 66.75% Intraday on Successful IPO Pricing Above Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1139874515","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139874515?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:46","pubTimestamp":1781110004,"startTime":"0","endTime":"0","summary":"Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.The significant surge is attributed to the company's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642422432","title":"NASDAQ TRADE HALT  IPO SECURITY RELEASED FOR QUOTATION AT 11:12 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2642422432","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642422432?lang=en_us&edition=fundamental","pubTime":"2026-06-10 23:12","pubTimestamp":1781104353,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  IPO SECURITY RELEASED FOR QUOTATION AT 11:12 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nAQN2M2Z41:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642429011","title":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 09:30 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2642429011","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642429011?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:30","pubTimestamp":1781098247,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 09:30 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nAQN2M2VD1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642944754","title":"Parabilis Medicines to Raise $745 Million in IPO, Private Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642944754","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642944754?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:03","pubTimestamp":1781085823,"startTime":"0","endTime":"0","summary":"Parabilis Medicines has priced an upsized initial public offering of 33.5 million shares at $20 per share, the company said Tuesday.Underwriters have been granted a 30-day option to purchase up to abo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU0058720904.USD","IPOS","LU1917777945.USD","REGN","BK4588","LU2362541273.HKD","LU2106854487.HKD","LU2362540622.SGD","PBLS","LU2237438978.USD","LU0114720955.EUR","LU0289739699.SGD","LU0823434583.USD","LU0889565916.HKD","LU0053666078.USD","LU1974910355.USD","LU0320765992.SGD","LU0823416689.USD","LU0823434740.USD","LU2468319806.SGD","LU0109394709.USD","LU0882574055.USD","LU2023250504.SGD","BK4139","LU2362541513.USD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198122444","title":"Parabilis Medicines, a Rising Star in Cancer Peptide Therapy, Prices IPO Above Range with 10x Oversubscription, Raising $745 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1198122444","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198122444?lang=en_us&edition=fundamental","pubTime":"2026-06-10 11:40","pubTimestamp":1781062844,"startTime":"0","endTime":"0","summary":"A U.S. biotechnology company focused on cancer treatments, Parabilis Medicines (PBLS.US), has completed an upsized U.S. IPO priced above its marketed range. Combined with a concurrent private...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642167419","title":"Parabilis Medicines 33.5M share IPO priced at $20.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2642167419","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642167419?lang=en_us&edition=fundamental","pubTime":"2026-06-10 09:35","pubTimestamp":1781055318,"startTime":"0","endTime":"0","summary":"The deal size was increased to 33.5M shares and priced above the $17.00-$19.00 target range. Leerink, BofA, Evercore ISI, Guggenheim and LifeSci Ca...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/parabilis-medicines-33-5m-share-ipo-priced-at-20-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/parabilis-medicines-33-5m-share-ipo-priced-at-20-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPOS","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642415198","title":"Parabilis Medicines Announces Pricing of Upsized Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642415198","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642415198?lang=en_us&edition=fundamental","pubTime":"2026-06-10 08:22","pubTimestamp":1781050920,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., June  09, 2026  (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309413/0/en/Parabilis-Medicines-Announces-Pricing-of-Upsized-Initial-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642246192","title":"Parabilis Medicines Boosts IPO to 33.3 Million Shares From 25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2642246192","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642246192?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:32","pubTimestamp":1781001120,"startTime":"0","endTime":"0","summary":"Parabilis Medicines has increased the size of a planned initial public offering that could give the clinical-stage biopharmaceutical company an initial market capitalization topping $2 billion.Parabilis on Tuesday said it now plans to sell more than 33.3 million shares at between $17 and $19 each in the IPO, up from prior plans to offer 25 million shares.At the $18 midpoint of that price range, the Cambridge, Mass., company said it expects net proceeds of about $553.1 million, or around $636.8 million if the underwriters exercise an option to buy an additional 5 million shares.Parabilis said it would have about 123.8 million shares outstanding after the IPO and a $75 million private placement with collaboration partner Regeneron Pharmaceuticals, assuming an exercise of the overallotment option, for a market capitalization of nearly $2.23 billion at the $18-a-share pricing midpoint.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}]}}